| 第 52 卷第 4 期 |  | Vol. 52 No. 4 | | 2022 年 8 月 | Aug 2022 |
|
所屬欄目：專(zhuān)論與綜述
EGFR抑制劑的研究進(jìn)展 |
| 謝月紅，周季穎，汪錦娟*
（南京醫科大學(xué)附屬南京醫院（南京市第一醫院）藥學(xué)部，江蘇 南京 210000） |
| 摘 要：肺癌是世界上癌癥死亡的主要原因，其中非小細胞肺癌占肺癌的80%以上。在非小細胞肺癌的治療中表皮生長(cháng)因子受體-酪氨酸激酶抑制劑（EGFR-TKIs）占有非常重要的地位。針對耐藥性問(wèn)題，目前小分子EGFR-TKIs共開(kāi)發(fā)了四代。綜述了EGFR抑制劑的研究進(jìn)展。 |
| 關(guān)鍵詞：小細胞肺癌；EGFR-TKIs；耐藥性 |
| 中圖分類(lèi)號：R734.2 文獻標識碼：A 文章編號：1009-9212（2022）04-0006-08 |
|
| Research Progress of EGFR Inhibitors |
| XIE Yue-hong, ZHOU Ji-ying, WANG Jin-juan*
(Department of Pharmacy, Nanjing First Hospital, Nanjing Medical University, Nanjing 210000, China) |
| Abstract：Lung cancer has affected human health seriously. Lung cancer provides the highest incidence rate and mortality rate in China while non-small cell lung cancer (NSCLC) accounts for 80% of lung cancer mortality. Epidermal growth factor receptor (EGFR) tyrosine kinase activity leads to recruitment and phosphorylation of several downstream intracellular substrates, leading to mitogenic signaling and tumor-promoting cellular activities. Therefore, inhibition of EGFR signaling pathway could significantly inhibit the growth and proliferation of tumor cells. The structures and functions of EGFR as well as current status of EGFR tyrosine kinase inhibitors were reviewed. |
| Key words：NSCLC; EGFR tyrosine kinase inhibitors; drug resistance |
|
作者簡(jiǎn)介：謝月紅（1987—），女，江蘇南京人，藥師，研究方向：藥學(xué)（E-mail: suifengzhuliuxz@163.com）。
|
聯(lián) 系 人：汪錦娟，主管藥師，研究方向：藥學(xué)。
|
收稿日期：2022-07-18
|
|